Ask VialBase
longevity

FOXO4-DRI

FDA: research-only

Foxo4-DRI (D-Retro-Inverso) is a novel senolytic peptide that selectively targets and neutralizes senescent ("zombie") cells by disrupting the Foxo4-p53 interaction, triggering apoptosis in damaged cells while leaving healthy cells intact. Selectively targets senescent cells by disrupting the interaction between Foxo4 and p53 proteins. In senescent cells, Foxo4 binds p53 to prevent apoptosis, keeping damaged cells alive. Foxo4-DRI competes for this binding, freeing p53 to trigger apoptosis specifically in senescent cells. Healthy cells are unaffected because they don't rely on this survival mechanism. - Selective senescent cell clearance - Anti-aging at the cellular level - Potential cancer protection (removes pre-cancerous senescent

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —
Half-life —
CAS number —
Route —
02

Sourcing

Current prices

Updated today

10mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep
Stocks this compound Third-party tested Public COAs

Save 50% via this link — discount auto-applied at checkout.

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC with differential
  • CRP
DURING CYCLE
  • CMP
  • CBC with differential
POST-CYCLE
  • CMP
  • CBC
  • CRP
Safety & Regulatory Status
FDA STATUS research-only

Regulatory status for FOXO4-DRI may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.